Coronavirus disease 2019 autoimmune inflammatory rheumatic diseases
Conditions
Interventions
None listed
Sponsors
The University of Osaka
Data Science Department, Shionogi &
Co.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The study period spans from January 1, 2020, to August 31, 2022. We identified patients diagnosed with COVID-19, which is categorized under the International Classification of Diseases, Tenth Revision (ICD-10), as U07.1 (COVID-19, virus identified) and U07.2 (COVID-19, virus not identified). These groups form the basis of our exposed cohort. To establish a control group, we selected individuals from the same dataset who were neither diagnosed with COVID-19 nor with B34.2 (unspecified viral infection), matching them with the exposed group based on relevant criteria. The exposed group (COVID-19 patients) includes individuals with a confirmed diagnosis coded either as U07.1 or U07.2 during the data period. Conversely, the control group (non-COVID-19 patients) consists of individuals who were not diagnosed with COVID-19 or B34.2 within the same timeframe. Additionally, the analysis will differentiate between groups based on the timing of COVID-19 infection, providing insights into the impact of infection waves and potentially differing strains of the virus.
Exclusion criteria
Exclusion criteria: Patients with AIIRD (Autoimmune/Inflammatory Rheumatic Diseases) diagnoses within the 6 months preceding COVID-19 infection will be excluded from the evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome was defined as the incidence of AIIRD onset within one year during the study period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes were evaluated as follows: 1. The presence or absence of each outcome associated with hospitalization. 2. Total medical costs incurred after the onset of AIIRD within 12 months following the Index Month (IM) (in yen). 3. The prescription of AIIRD-specific medications. 4. The period from the IM to hospitalization following the onset of AIIRD (in months). The Index Month is defined as the earliest month of COVID-19 diagnosis between July 2019 and August 2023. Additionally, a sensitivity analysis was performed by excluding medications that could potentially be used for COVID-19 treatment (dexamethasone, tocilizumab, sarilumab, baricitinib) from the list of drugs used to determine AIIRD-specific prescriptions. The sensitivity analysis was conducted for the main outcome, which is the frequency distribution, and the exploratory outcome, which is the period from the month of COVID-19 diagnosis to hospitalization after the onset of AIIRD. All of these analyses were conducted as post hoc analyses. | — |
Countries
Japan
Contacts
Public ContactRyuichi Sada
Graduate School of Medicine, The University of Osaka Department of Transformative Analysis for Human Specimen
Outcome results
None listed